{"entity":{"id":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","kind":"paper","name":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","aka":[],"tldr":"In one of the most lethal cancers known, dabrafenib plus trametinib shrank BRAF-mutant anaplastic thyroid cancer in about two thirds of patients, leading to the first ever drug approval for the disease.","summary":"Anaplastic thyroid cancer cohort of the phase 2 ROAR basket trial: 16 patients with BRAF V600E-mutant locally advanced or metastatic anaplastic thyroid cancer treated with dabrafenib plus trametinib.\n\nObjective response was 69 percent with responses lasting more than a year in most, twelve-month overall survival of about 80 percent in an updated analysis, and manageable toxicity; the approval followed in 2018.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2018","url":"https://doi.org/10.1200/JCO.2017.73.6785"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29072975/"}],"tags":[],"related":[],"cancers":["anaplastic-thyroid-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dabrafenib","trametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/JCO.2017.73.6785","pmid":"29072975","authors":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.","paperType":"observational","findings":["Objective response 69 percent (11 of 16).","Median duration of response and survival substantially exceeding historical months."],"whatItMeans":"Rapid BRAF testing is mandatory at diagnosis of anaplastic thyroid cancer, and BRAF-MEK inhibition, increasingly with pembrolizumab and as neoadjuvant therapy, is the standard for BRAF-mutant disease.","caveats":["Very small cohort; only about 40 percent of anaplastic thyroid cancers carry BRAF V600E."],"changedPractice":true,"participants":16},"route":"/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/","neighbours":{"cancer":[{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/"}],"drug":[{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/"},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}